fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Trimethoprim

All products: general benefit

Trimethoprim · DIN 02243116 · 100 mg · tablet

General benefitMarketed · checked October 5, 2026
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
1 brand, same coverage
Trimethoprim · DIN 02243116 Manufacturer: A A Pharma Inc.; listing date 2001-06-07 Daily cost (source): $0.5234 Health Canada: Marketed since 2011-05-07 · brand TRIMETHOPRIM TABLETS · ATC J01EA01 TRIMETHOPRIM · form Tablet · route Oral · ingredients TRIMETHOPRIM 100 MG · company Aa pharma inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Trimethoprim: Formulary list price $0.26 per unit (the source does not state the unit; exact figure $0.2617). What the ministry pays, not the patient.

Ministry pays: $0.2617 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02243116)

Source record
DIN 02243116: Trimethoprim Raw flags: sec3=Y Item: 084000007; group id 140; item number 0235; lccId None; manufacturer id AAP Source form: Tab; strength: 100mg Recorded listing: General benefit Source prices (unrounded): $0.2617; ministry $0.2617 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02243116 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=66985
Interchangeable products
Proloprim · DIN 00675229 · not recorded
Shortage status: resolved shortage (ended March 29, 2023); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243116
Shortage record checked October 6, 2026

Other products in the same Health Canada class (J01E): coverage varies; not interchangeable

  • Sulfamethoxazole + trimethoprim (Septra): general benefit, not a benefit
Other drugs in the same formulary class (08:40 Miscellaneous Anti-Infectives) and how they are covered

Matched class: 08:40 Miscellaneous Anti-Infectives

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Some products covered without a code (check the product listing): CIPROFLOXACIN, LEVOFLOXACIN, MOXIFLOXACIN HYDROCHLORIDE, NORFLOXACIN, SULFAMETHOXAZOLE & TRIMETHOPRIM 08:40 Miscellaneous Anti-Infectives

SULFAMETHOXAZOLE & TRIMETHOPRIM

· 9 products · Listed, not a benefit (6), General benefit (3) · strengths: 40mg & 8mg/mL, 400mg & 80mg, 800mg & 160mg · O/L, Tab

CIPROFLOXACIN

· 44 products · Limited Use, codes 533 (1), Listed, not a benefit (3), General benefit (40) · strengths: 10g/100mL, 250mg, 500mg, 750mg · Oral Susp, Tab

LEVOFLOXACIN

· 24 products · Listed, not a benefit (2), General benefit (14), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 250mg, 500mg, 750mg · Tab

MOXIFLOXACIN HYDROCHLORIDE

· 12 products · Listed, not a benefit (1), General benefit (11) · strengths: 400mg · Tab

NORFLOXACIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 400mg · Tab

CIPROFLOXACIN HCL & CIPROFLOXACIN BASE

· 2 products · Listed, not a benefit (1), Limited Use, codes 394 (1) · strengths: 500mg · ER Tab

LINEZOLID

· 7 products · Off-Formulary Interchangeable, not an ODB benefit (3), Listed, not a benefit (1), Limited Use, codes 362, 363, 364 (3) · strengths: 2mg/mL, 600mg · Inj-300mL Pk, Tab

CEFEPIME

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g, 2g · Inj Pd-Vial Pk

ERTAPENEM

· 5 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 1g/Vial · Inj Pd-Vial Pk Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 08:40
Full class listing Related classes: 08:08 Anthelmintics, 08:12 Antibiotics, 08:14 Antifungals, 08:16 Antitubercular Agents, 08:18 Antivirals, 08:20 Plasmodicides (Antimalarials), 08:24 Sulfonamides, 08:30 Antiprotozoals, 08:32 Trichomonacides, 08:36 Urinary Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: uncomplicated urinary tract infections
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CEFADROXIL · Listed, not a benefit (1), General benefit (3) • Acute uncomplicated urinary tract infections when caused by E.coli, Klebsiella species and some strains of Proteus mirabilis. PM: https://pdf.hres.ca/dpd_pm/00056563.PDF; date May 20, 2020; DIN 02235134; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-09-22
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE For the treatment of acute, uncomplicated urinary tract infections due to susceptible strains of Escherichia coli and Klebsiella pneumoniae. Limited clinical experience suggests the probability of therapeutic response in infections due to susceptible strains of Proteus mirabilis and Enterobacter species. Cultures and susceptibility tests should be performed to determine the susceptibility of the bacteria to trimethoprim. Therapy may be initiated prior to obtaining the results of these tests. For infections associated with urinary tract complications such as obstruction, or where tissue involvement is suspected, the combination of trimethoprim/sulfamethoxazole has been shown to be superior to trimethoprim alone. https://pdf.hres.ca/dpd_pm/00025165.PDF PM date: May 14, 2014 Source product: TRIMETHOPRIM TABLETS; DIN 02243116; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.